CLSDライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:41):

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space...

Stats
本日の出来高	49 195.00
平均出来高	371 225
時価総額	97.51M
EPS	$0 ( 2024-03-12 )
次の収益日	( $-0.140 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.46
ATR14	$0.0140 (1.07%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Gibney Anthony S	Buy	93 290	Common Stock
2024-04-17	Gibney Anthony S	Buy	6 710	Common Stock
2024-04-15	Gibney Anthony S	Buy	45 000	Stock Option (right to buy)
2024-04-15	Gibney Anthony S	Buy	0
2024-03-20	Chong Ngai Hang Victor	Buy	30 000	Common Stock

INSIDER POWER
66.58
Last 97 transactions
Buy: 5 495 368 \| Sell: 2 175 231

ボリューム相関

長: 0.01 (neutral)

短: -0.17 (neutral)

Signal:(46.737) Neutral

Clearside Biomedical Inc 相関

10 最も正の相関
BNIXU	0.821
HOTH	0.802

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Clearside Biomedical Inc 相関 - 通貨/商品

-0.17
( neutral )

-0.10
( neutral )

0.00
( neutral )

0.11
( neutral )

0.49
( neutral )

0.02
( neutral )

Clearside Biomedical Inc 財務諸表

Annual	2023
収益:	$8.23M
総利益:	$7.80M (94.87 %)
EPS:	$-0.530

FY	2023
収益:	$8.23M
総利益:	$7.80M (94.87 %)
EPS:	$-0.530

FY	2022
収益:	$1.33M
総利益:	$1.12M (84.63 %)
EPS:	$-0.570

FY	2021
収益:	$29.58M
総利益:	$29.58M (100.00 %)
EPS:	$0.00632

Financial Reports:

No articles found.

Clearside Biomedical Inc

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.